Kuribayashi Ami, Kataoka Keiko, Kurabayashi Tohru, Miura Masahiko
Molecular Diagnosis and Therapeutics, Department of Oral Restitution, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8549, Japan.
Endocrinology. 2004 Nov;145(11):4976-84. doi: 10.1210/en.2004-0713. Epub 2004 Jul 22.
IGF-I receptor (IGF-IR) is involved in numerous biological functions via its major downstream signaling molecules, extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3'-kinase/Akt. The IGF-I-induced activation of ERK, but not that of Akt, is reportedly mediated by the transactivation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK). The mechanism for the EGFR-TK-dependent activation, however, still remains largely unknown. We found that an oral carcinoma cell line overexpressing EGFR, Ca9-22, exhibited IGF-I-induced activation of both Akt and ERK, but that only the latter was significantly decreased by a specific inhibitor of EGFR-TK, tyrphostin AG1478. In this report we provide evidence for the existence in this cell line of a novel mechanism by which IGF-I induces ERK activation in a manner that is dependent on the basal level of EGFR-TK activity, but is independent of receptor transactivation. In addition, we show that c-Raf kinase is likely to be a key regulator of this mechanism. The elucidation of such a unique mechanism involving cross-talk between EGFR and heterologous receptors may shed additional light on the clinical use of EGFR-TK inhibitors in antitumor therapies.
胰岛素样生长因子-I受体(IGF-IR)通过其主要的下游信号分子,即细胞外信号调节激酶(ERK)和磷脂酰肌醇3'-激酶/蛋白激酶B(Akt),参与多种生物学功能。据报道,IGF-I诱导的ERK激活,而非Akt的激活,是由表皮生长因子受体(EGFR)酪氨酸激酶(TK)的反式激活介导的。然而,EGFR-TK依赖性激活的机制在很大程度上仍然未知。我们发现,过表达EGFR的口腔癌细胞系Ca9-22表现出IGF-I诱导的Akt和ERK激活,但只有后者被EGFR-TK的特异性抑制剂 tyrphostin AG1478显著降低。在本报告中,我们提供证据表明,在该细胞系中存在一种新机制,通过该机制IGF-I以依赖于EGFR-TK活性基础水平但独立于受体反式激活的方式诱导ERK激活。此外,我们表明c-Raf激酶可能是该机制的关键调节因子。阐明这种涉及EGFR与异源受体相互作用的独特机制,可能会为EGFR-TK抑制剂在抗肿瘤治疗中的临床应用提供更多启示。